IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-03-31

Study Completion Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate efficacy and tolerability of Ziprasidone IM and oral in agitated patients with acute exacerbation of schizophrenia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study

NCT00645320

Pyschotic Disorders

COMPLETED PHASE4

Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia

NCT00139737

Schizophrenia

COMPLETED PHASE3

A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT00645229

Schizophrenia Schizoaffective Disorder

TERMINATED PHASE3

A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT00650429

Schizophrenia Schizoaffective Disorder

COMPLETED PHASE4

Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia

NCT00265382

Schizophrenia

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ziprasidone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Psychiatric:
* Diagnosis of schizophrenia using DSM-IV (295.xx).
* Patients entering hospital (or inpatients transferring to higher-dependency unit) within the previous seven days because of acute exacerbation of psychotic symptoms.
* PANSS \> 80 (score Â³ 3 on at least three of the following PANSS agitation items: anxiety , tension, hostility, excitement).
* CGI-S Â³ 4. - Indication, based on intensity/severity of psychotic symptoms, on IM therapy.
* General:
* Male or Female patients aged 18-60 years at screening.
* Written informed consent to participation.
* Female patients of at risk of pregnancy must avoid to remain pregnant; an adequate method of contraception can be initiated or continued.

Exclusion Criteria

* Psychiatric:
* Patients at immediate risk of committing harm to self or others
* Concurrent treatment with other antipsychotic agents after baseline
* Patients receiving depot antipsychotic medication within 21 days of screening
* Treatment with antidepressants or mood stabilizers (such as lithium, carbamazepine, valproic acid or verapamil) within two weeks of screening
* Diagnosis of substance abuse using DSM-IV criteria within previous 12 months
* Positive urine drug screen at screening for amphetamine, cocaine or opioids
* Alcohol and/or any other drug abuse at screening
* Patients who have received clozapine within 3 months prior to screening due to intolerance to other antipsychotics or patients who have received clozapine in the past two years for refractoriness to treatment
* Treatment with any investigational agent within the previous six months
* Previous treatment with ziprasidone
* Organic mental disease, including mental retardation
* History of psychosurgery
* General:
* Patients with a history of clinically significant and/or currently relevant hematological, renal (including single kidney), hepatic, gastrointestinal, endocrine (except for current adequately treated hypo- or hyperthyroidism), pulmonary (excluding chronic bronchitis, mild emphysema or chronic obstructive pulmonary disease), dermatological, oncological, or neurological disease, excluding tardive dyskinesia but including all forms of epilepsy (febrile convulsions in childhood acceptable). The only patients with known prior malignant disease who are eligible are those with cured prior skin cancer (excluding melanoma). Controlled Type II diabetes (glucose \< 180 mg/100 ml at screening and baseline with dietary or oral hypoglycemic treatment) will not be considered a significant medical illness and would not exclude a subject from the study - Patients with a history of significant cardiovascular disease or significant concurrent cardiovascular disease, including a history of uncontrolled hypertension (supine diastolic pressure \>95 mm Hg and/or supine systolic pressure \> 170 mm Hg with or without treatment)
* Clinically significant ECG abnormality
* Patient with QTc Â³ 450 msec - Concomitant treatment with medications that prolong QT interval
* Patients with serum K+ or Mg++ outside the normal range
* Confirmed clinically significant laboratory values.
* Known serological evidence of HIV, or acute or chronic hepatitis (with transaminase levels higher than three times the normal limits)
* Patients who intend to donate blood or blood products during the 4 weeks prior to the study, during the study or in the 30 days after the study ends
* Patients unable or unlikely to follow the study protocol
* Pregnant or lactating women
* Patients with a history of neuroleptic malignant syndrome developing from the administration of antipsychotic compounds
* Known hypersensitivity to ziprasidone or lactose

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No